REVIEW

Aspects of informing and obtaining consent while conducting trials in pulmonology and psychiatry

Sinitsina II, Nenascheva NM, Peredelskaya MYu, Sosin DN
About authors

Russian Medical Academy of Continuous Professional Training, Moscow, Russia

Correspondence should be addressed: Irina I. Sinitsina
ul. Barrikadnaya, 2/1, str. 1, Moscow, 125993, Russia; ur.liam@aniri-anistinis

About paper

Author contribution: Sinitsina II — preparing a manuscript for publication, literature analysis, editing, writing an introduction, abstract and ‘Vulnerable participants or patients’ section; Nenascheva NM — preparing a manuscript for publication, analysis of literature for ‘Specific nature of obtaining informed consent from patients with bronchial asthma and chronic obstructive pulmonary disease’ section; Peredelskaya MYu — preparing a manuscript for publication, analysis of literature for ‘Specific nature of obtaining informed consent from patients with bronchial asthma and chronic obstructive pulmonary disease’ section; Sosin DN — preparing a manuscript for publication, analysis of literature for ‘Specific nature of obtaining informed consent from psychiatric patients’ section.

Received: 2022-01-22 Accepted: 2022-02-25 Published online: 2022-03-30
|

While obtaining voluntary informed consent from patients with chronic obstructive pulmonary disease (COPD), bronchial asthma and patients presenting with psychiatric symptomology who participate in clinical trials, it is necessary to remember not only about the rights and ethical standards, but also about an extremely vulnerable position of the participants due to their disease specificity. Changes in the mental status of the patients and principal problems of every patient need to be considered. In this article, the aspects of obtaining informed consent from patients with respiratory diseases such as bronchial asthma and COPD and those under psychiatric supervision are reviewed. Apart from general recommendations, every category of patients has its own specific features. Being aware of them will improve doctor-patient communication.

Keywords: chronic obstructive pulmonary disease, bronchial asthma, depression, informed consent, clinical trial, vulnerable groups, schizophrenia

КОММЕНТАРИИ (0)